Previous 10 | Next 10 |
ART12.11, a novel and patented cocrystal of CBD reverses the impact of chronic stress on outcomes of anxiety, depression, sociability and cognition ART12.11 aims to address unmet needs within the global anxiety and depression market estimated to be in excess of $11 billion SOLANA...
SOLANA BEACH, Calif., June 07, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. ( Nasdaq: ARTL ), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, t...
2023-05-11 09:40:34 ET Artelo Biosciences press release ( NASDAQ: ARTL ): Q1 GAAP EPS of -$0.76. As of March 31, 2023, the Company had approximately $15.5 million in cash and investments, compared to $17.5 million as of December 31, 2022. For further details see: ...
SOLANA BEACH, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. ( Nasdaq: ARTL ) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today r...
2023-04-28 12:33:58 ET Gainers: AGBA Group Holding ( AGBA ) +134% . Huadi International Group ( HUDI ) +55% . Top KingWin ( TCJH ) +50% . MultiMetaVerse Holdings ( MMV ) +44% . U Power Limited Ordinary ( UCAR ) +4...
2023-04-25 10:06:07 ET Gainers: Baudax Bio ( BXRX ) +48% . Petros Pharmaceuticals ( PTPI ) +48% . Morphic Holding ( MORF ) +22% . Arrowhead Pharmaceuticals ( ARWR ) +17% . Medpace Holdings ( MEDP ) +17% . Losers: Trac...
SOLANA BEACH, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today annou...
2023-03-31 08:49:48 ET Artelo Biosciences press release ( NASDAQ: ARTL ): FY GAAP EPS of -$3.56. As of December 31, 2022, the Company had approximately $17.5 million in cash and marketable securities, compared to $25.6 million as of December 31, 2021 For further deta...
SOLANA BEACH, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. ( Nasdaq:ARTL ), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today repor...
SOLANA BEACH, CA / ACCESSWIRE / February 15, 2023 / Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that it...
News, Short Squeeze, Breakout and More Instantly...
Artelo Biosciences Inc. Company Name:
ARTL Stock Symbol:
OTCMKTS Market:
Artelo Biosciences Inc. Website:
SOLANA BEACH, Calif., July 03, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological condit...
Inhibition of FABP5 Demonstrates Activity in Cancer, Psoriasis, and Anxiety Disorders Results from Several Research Studies Presented at the Annual ICRS Symposium SOLANA BEACH, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a c...
SOLANA BEACH, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological condit...